Management of Rhesus Alloimmunization in Pregnancy

@article{Moise2008ManagementOR,
  title={Management of Rhesus Alloimmunization in Pregnancy},
  author={Kenneth J. Moise},
  journal={Obstetrics \& Gynecology},
  year={2008},
  volume={112},
  pages={164-176}
}
  • K. Moise
  • Published 1 September 2002
  • Medicine
  • Obstetrics & Gynecology
Rhesus immune globulin has decreased the prevalence of rhesus D alloimmunization in pregnancy so that only approximately six cases occur in every 1,000 live births. The rarity of this condition warrants consideration of consultation with or referral to a maternal–fetal medicine specialist with experience in the monitoring and treatment of patients with red cell alloimmunization in pregnancy. Evaluation for the presence of maternal anti-D antibody should be undertaken at the first prenatal visit… 
ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy.
  • Medicine
    Obstetrics and gynecology
  • 2018
TLDR
Advances in Doppler ultrasonography have led to the development of noninvasive methods of management of alloimmunization in pregnant women, and together with more established protocols, this may allow for a more thorough and less invasive workup with fewer risks to the mother and fetus.
Successful Management of Anti-Jra Alloimmunization in Pregnancy: A Case Report
TLDR
PSV-MCA should be monitored for the detection of fetal anemia, even in pregnant women sensitized to some antigens for which only routine obstetrical care is recommended.
Noninvasive approaches to the management of RhD hemolytic disease of the fetus and newborn
TLDR
A novel approach is proposed in this volume of TRANSFUSION by Nielsen and colleagues, who report in vitro results of recombinant mutant IgG anti-D deficient in hemolytic activity that are designed to block the hemolytestic activity of maternalAnti-D responsible for HDFN.
Rh sensitized pregnancy with high ICT titre with favourable foetal outcome: a rare case -
TLDR
A rare case of Rh sensitized pregnancy with high ICT titre who had normal fetal outcome is presented.
Plasmapheresis and intravenous immune globulin for the treatment of D alloimmunization in pregnancy
TLDR
A case report of an Rh(D) alloimmunized pregnancy, in which successful management consisted of initial therapeutic plasmapheresis followed by intravenous immunoglobulin (IVIG) administration until delivery at 37 weeks gestation without the need for intrauterine transfusion.
A case of D alloimmunization in pregnancy: successfully treated solely with therapeutic plasma exchange (TPE)
TLDR
It is reported here the successful management of a case of D alloimmunization in pregnancy solely with TPE, without the need for IUT, in a 33-year-old G4, L2, and D1, who had a history of alloIMmunized in her previous pregnancy.
Hemolytic Disease of the Newborn: A Review of Current Trends and Prospects
TLDR
The disorder’s etiology, diagnosis, and management, including the most current findings as of 2021, are covered, as well as trends and prospects, to help in future research and evidence-based medical practice.
Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy.
TLDR
It appears that IM and IV administration of anti-D are equally effective, and insufficient information is found upon which to guide practice due to the limited number of included studies, small sample sizes and methodological limitations.
A curious case of anti-D antibody titer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 79 REFERENCES
An animal model for hemolytic disease of the fetus and newborn. II. Fetal effects in New Zealand rabbits.
Doppler Ultrasonography Versus Amniocentesis to Predict Fetal Anemia
TLDR
Doppler measurement of the peak velocity of systolic blood flow in the middle cerebral artery can safely replace invasive testing in the management of Rh-alloimmunized pregnancies.
Paternal leukocyte alloimmunization as a treatment for hemolytic disease of the newborn in a rabbit model.
TLDR
Maternal alloimmunization to paternal leukocytes decreases the severity of hemolytic disease and may play a role in the treatment of severe hemolytics disease of the newborn in humans.
Intraperitoneal Transfusion in Severe, Early-Onset Rh Isoimmunization
TLDR
This series shows that intraperitoneal transfusions can be used to successfully treat severe, early-onset Rhesus disease, suggesting that even at 15 to 16 weeks of gestation it correlates with fetal hemoglobin.
Management of Late Anemia in Rhesus Hemolytic Disease: Use of Recombinant Human Erythropoietin (A Pilot Study)
TLDR
It is demonstrated that recombinant human erythropoietin treatment decreases the need for erythrocyte transfusions in the late anemia of infants with Rh isoimmunization, considering the risks of blood transfusions, this decrease in the donor exposure is worthwhile.
...
1
2
3
4
5
...